X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (28) 28
humans (25) 25
female (18) 18
male (14) 14
article (11) 11
adult (10) 10
oncology (10) 10
cancer (9) 9
mutation (9) 9
health aspects (8) 8
pregnancy (8) 8
genetic aspects (7) 7
obstetrics & gynecology (7) 7
patients (7) 7
tumors (7) 7
animals (6) 6
child (6) 6
gliomas (6) 6
infant, newborn (6) 6
abstracts (5) 5
brain neoplasms - genetics (5) 5
child, preschool (5) 5
gene mutations (5) 5
glioma - genetics (5) 5
infant (5) 5
mice (5) 5
prognosis (5) 5
brain neoplasms - pathology (4) 4
cell biology (4) 4
children (4) 4
clinical neurology (4) 4
clonal evolution (4) 4
disease progression (4) 4
dna methylation (4) 4
genomes (4) 4
glioma - pathology (4) 4
identification (4) 4
methylation (4) 4
middle aged (4) 4
perinatal outcome (4) 4
prospective studies (4) 4
risk factors (4) 4
abridged index medicus (3) 3
anomalies (3) 3
antineoplastic agents - therapeutic use (3) 3
brain neoplasms - drug therapy (3) 3
care and treatment (3) 3
case-control studies (3) 3
cesarean section (3) 3
chemotherapy (3) 3
clinical trials (3) 3
deoxyribonucleic acid--dna (3) 3
disease-free survival (3) 3
dna (3) 3
dna copy number variations (3) 3
endocrinology (3) 3
epigenetic inheritance (3) 3
gene expression (3) 3
genetics (3) 3
genomics (3) 3
gestational age (3) 3
glioma - drug therapy (3) 3
growth (3) 3
gynecology (3) 3
health risk assessment (3) 3
human genetics (3) 3
idh1 (3) 3
influenza (3) 3
isocitrate dehydrogenase - metabolism (3) 3
leukemia (3) 3
leukemia, myelomonocytic, juvenile - genetics (3) 3
low-grade gliomas (3) 3
medical prognosis (3) 3
medicine & public health (3) 3
mice, inbred c57bl (3) 3
multidisciplinary sciences (3) 3
mutation - genetics (3) 3
mutations (3) 3
neoplasm grading (3) 3
obstetrics/perinatology (3) 3
pathology (3) 3
polyhydramnios - complications (3) 3
pregnancy outcome (3) 3
reproductive biology (3) 3
research (3) 3
sequencing data (3) 3
survival (3) 3
temozolomide (3) 3
2hg (2) 2
abstracts from the 20th annual scientific meeting of the society for neuro-oncology (2) 2
acute disease (2) 2
adolescent (2) 2
adults (2) 2
aged (2) 2
analysis (2) 2
ancient cities (2) 2
antineoplastic agents, alkylating - therapeutic use (2) 2
apdm09 (2) 2
apgar score (2) 2
binding sites (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science, ISSN 0036-8075, 2014, Volume 343, Issue 6167, pp. 189 - 193
Journal Article
Nature Genetics, ISSN 1061-4036, 11/2015, Volume 47, Issue 11, pp. 1326 - 1333
Journal Article
Acta neuropathologica, ISSN 0001-6322, 2015, Volume 129, Issue 4, pp. 597 - 607
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2017, Volume 114, Issue 40, pp. 10743 - 10748
Journal Article
Cancer Research, ISSN 0008-5472, 01/2016, Volume 76, Issue 2 Supplement, pp. IA08 - IA08
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 12/2017, Volume 123, Issue 23, pp. 4631 - 4639
The inhibition of mammalian target of rapamycin with everolimus has yielded a high rate of clinical stability in a phase 2 clinical trial of patients with... 
clinical trial | perfusion imaging | phosphatidylinositol 3‐kinase (PI3K) pathway | everolimus | low‐grade gliomas | phosphatidylinositol 3-kinase (PI3K) pathway | low-grade gliomas | MAMMALIAN TARGET | NERVOUS-SYSTEM | GLIOBLASTOMA-MULTIFORME | RESPONSE ASSESSMENT | KINASE | II TRIAL | TUMORS | TEMOZOLOMIDE | THERAPY | ONCOLOGY | GROWTH | Prospective Studies | Follow-Up Studies | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Humans | Middle Aged | Brain Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Male | Survival Rate | Antineoplastic Agents - therapeutic use | Brain Neoplasms - drug therapy | Neoplasm Recurrence, Local - pathology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Neoplasm Grading | Glioma - pathology | Adult | Everolimus - therapeutic use | Female | Aged | Gene Expression Regulation, Neoplastic - drug effects | Neoplasm Staging | Glioma - drug therapy | Immunohistochemistry | Care and treatment | Cancer patients | Gliomas | Analysis | Rapamycin | Dosage and administration | TOR protein | Stability | Medical treatment | Membrane permeability | Medical services | Clinical trials | Population studies | Permeability | Mammals | Kinases | Patients | Survival | 1-Phosphatidylinositol 3-kinase | Inhibitors | Magnetic resonance imaging | Blood volume | Perfusion | Magnetic permeability | Antiangiogenics | Quality | Medical prognosis | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2017, Volume 23, Issue 7, pp. 1852 - 1861
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 07/2018, Volume 65, Issue 7, pp. e27034 - n/a
BackgroundMost patients with juvenile myelomonocytic leukemia (JMML) are curable only with allogeneic hematopoietic cell transplantation (HCT). However, the... 
juvenile myelomonocytic leukemia | hematopoietic cell transplantation | mutant allele burden | conditioning regimens | GENE-MUTATIONS | SURVIVAL | CRITERIA | EWOG-MDS | FLUDARABINE | ONCOLOGY | PATHWAY | CLINICAL-TRIALS | PEDIATRICS | STEM-CELL TRANSPLANTATION | RETROSPECTIVE ANALYSIS | HEMATOLOGY | MYELODYSPLASTIC SYNDROMES | Graft Rejection - drug therapy | Prognosis | Follow-Up Studies | Leukemia, Myelomonocytic, Juvenile - therapy | Humans | Child, Preschool | Graft Rejection - etiology | Infant | Male | Vidarabine - analogs & derivatives | Busulfan - administration & dosage | Leukemia, Myelomonocytic, Juvenile - complications | Graft vs Host Disease - drug therapy | Hematopoietic Stem Cell Transplantation - adverse effects | Myeloablative Agonists - administration & dosage | Female | Vidarabine - administration & dosage | Transplantation Conditioning | Child | Graft vs Host Disease - etiology | Infant, Newborn | Leukemia | Oncology, Experimental | Mortality | Clinical trials | Transplantation | Research | Hematopoietic stem cells | Chemotherapy | Gene mutations | Analysis | Influenza | Lymphomas | Health aspects | Cancer | Myelomonocytic leukemia | Disease control | Patients | Morbidity | Molecular chains | Risk factors | Hemopoiesis | Cyclophosphamide | Randomization | Fludarabine | Alleles | Melphalan | Diagnostic systems | Children | Busulfan | Conditioning | Risk management | Index Medicus
Journal Article